title: Good manufacturing practice-grade cytotoxic T lymphocytes specific for latent membrane proteins (LMP)-1 and LMP2 for patients with Epstein-Barr virus-associated lymphoma.
authors.affiliation: Center for Cell and Gene Therapy, Department of Pediatrics, Baylor College of Medicine, The Methodist Hospital and Texas Children's Hospital, Houston, Texas 77030, USA. cmbollar@txccc.org
authors.forename: Catherine M
authors.initials: CM
authors.lastname: Bollard
authors.forename: Stephen
authors.initials: S
authors.lastname: Gottschalk
authors.forename: M
authors.initials: M
authors.lastname: Helen Huls
authors.forename: Ann M
authors.initials: AM
authors.lastname: Leen
authors.forename: Adrian P
authors.initials: AP
authors.lastname: Gee
authors.forename: Cliona M
authors.initials: CM
authors.lastname: Rooney
mesh_terms: D000938:Antigen-Presenting Cells / Q000276:immunology; D018929:Cell Culture Techniques; D045744:Cell Line, Tumor; D002469:Cell Separation / Q000379:methods; D020031:Epstein-Barr Virus Infections / Q000150:complications / Q000628:therapy*; D004854:Herpesvirus 4, Human / Q000276:immunology*; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000379:methods*; D008223:Lymphoma / Q000628:therapy* / Q000821:virology; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology* / Q000637:transplantation*; D014161:Transduction, Genetic; D014763:Viral Matrix Proteins / Q000276:immunology*
chemical_list: C037662:EBV-associated membrane antigen, Epstein-Barr virus; D014763:Viral Matrix Proteins